Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 5.2% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 3,271,207 shares of the biopharmaceutical company's stock after selling 180,880 shares during the period. Geode Capital Management LLC owned about 2.10% of Ocular Therapeutix worth $28,464,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of OCUL. Barclays PLC increased its holdings in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after purchasing an additional 138,441 shares in the last quarter. Wellington Management Group LLP grew its position in Ocular Therapeutix by 47.1% during the third quarter. Wellington Management Group LLP now owns 462,864 shares of the biopharmaceutical company's stock valued at $4,027,000 after buying an additional 148,310 shares during the period. Polar Asset Management Partners Inc. purchased a new position in Ocular Therapeutix in the third quarter valued at $4,288,000. Patient Square Capital LP acquired a new position in shares of Ocular Therapeutix in the third quarter worth about $2,049,000. Finally, HighVista Strategies LLC boosted its stake in shares of Ocular Therapeutix by 5.1% during the 3rd quarter. HighVista Strategies LLC now owns 65,027 shares of the biopharmaceutical company's stock worth $566,000 after acquiring an additional 3,168 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL traded down $0.10 during midday trading on Friday, hitting $8.44. The stock had a trading volume of 1,106,634 shares, compared to its average volume of 1,750,961. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The stock has a 50 day simple moving average of $9.79 and a 200-day simple moving average of $8.67. The company has a market capitalization of $1.33 billion, a PE ratio of -6.39 and a beta of 1.19. Ocular Therapeutix, Inc. has a 1 year low of $3.76 and a 1 year high of $11.77.

Analysts Set New Price Targets

OCUL has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank assumed coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Ocular Therapeutix presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.71.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the sale, the insider now owns 269,059 shares in the company, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is currently owned by insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.